Undisclosed Cancer Metabolism Program(s)
Oncology
PreclinicalActive
Key Facts
About AddexBio
AddexBio is a hybrid-stage biotech company that combines an internal oncology drug discovery pipeline with an extensive portfolio of preclinical contract research services (CRO). Its core focus is on developing small molecules that disrupt cancer metabolism, a promising therapeutic approach. The company leverages its service arm to generate revenue and potentially de-risk its own R&D efforts. AddexBio appears to be a private, preclinical-stage company operating in the competitive but high-potential oncology space.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |